{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:21:33Z","timestamp":1763767293296,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007543","name":"National Agency for Safety of Medicines and Health Products","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.yebeh.2021.108449","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T06:37:24Z","timestamp":1637822244000},"page":"108449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Impact of recommendations on sodium valproate prescription among women with epilepsy: An interrupted time-series study"],"prefix":"10.1016","volume":"125","author":[{"given":"Adeline","family":"Degremont","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Polard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Kerbrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Grimaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie-Pierre","family":"Jonville-B\u00e9ra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Ringa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Travers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Oger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Biraben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.yebeh.2021.108449_b0005","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108449_b0010","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.yebeh.2021.108449_b0015","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1007\/s00415-012-6509-3","article-title":"Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany\u2014a nationwide population-based study in children and adults","volume":"259","author":"Hamer","year":"2012","journal-title":"J Neurol"},{"issue":"8304","key":"10.1016\/j.yebeh.2021.108449_b0020","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(82)90908-4","article-title":"Maternal valproic acid and congenital neural tube defects","volume":"320","author":"Robert","year":"1982","journal-title":"The Lancet"},{"key":"10.1016\/j.yebeh.2021.108449_b0025","doi-asserted-by":"crossref","unstructured":"Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst. Rev., John Wiley & Sons, Ltd; 2016. doi: 10.1002\/14651858.CD010224.pub2.","DOI":"10.1002\/14651858.CD010224.pub2"},{"issue":"7","key":"10.1016\/j.yebeh.2021.108449_b0030","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/adc.2009.176990","article-title":"Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine","volume":"96","author":"Cummings","year":"2011","journal-title":"Arch Dis Child"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108449_b0035","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol"},{"issue":"16","key":"10.1016\/j.yebeh.2021.108449_b0040","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.yebeh.2021.108449_b0045","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/epi.13007","article-title":"Prospective assessment of autism traits in children exposed to antiepileptic drugs during pregnancy","volume":"56","author":"Wood","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108449_b0050","unstructured":"European Medicines Agency. CMDh agrees to strengthen warnings on the use of valproate medicines in women and girls. http:\/\/www.ema.europa.eu\/ 2014. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/valproate-related-substances (accessed February 1, 2017)."},{"key":"10.1016\/j.yebeh.2021.108449_b0055","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament (ANSM)its de sant\u00e9. New prescription and delivery conditions for valproate and its derivatives linked to the risks associated to their use during pregnancy - Dear Doctor Letter 2015. https:\/\/ansm.sante.fr\/dossiers-thematiques\/medicaments-et-grossesse\/valproate-et-grossesse (accessed April 19, 2021)."},{"issue":"9","key":"10.1016\/j.yebeh.2021.108449_b0060","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/pds.3480","article-title":"A critical review of methods to evaluate the impact of FDA regulatory actions","volume":"22","author":"Briesacher","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.yebeh.2021.108449_b0065","unstructured":"Hautre Autorit\u00e9 de Sant\u00e9. Outcome indicators measured from medico-administrative databases. Haute Aut Sant\u00e9 n.d. https:\/\/www.has-sante.fr\/jcms\/p_3076997\/en\/outcome-indicators-measured-from-medico-administrative-databases (accessed April 26, 2021)."},{"issue":"8","key":"10.1016\/j.yebeh.2021.108449_b0070","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jclinepi.2014.12.018","article-title":"Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations","volume":"68","author":"Jandoc","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.yebeh.2021.108449_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2020.02.006","article-title":"Design characteristics and statistical methods used in interrupted time series studies evaluating public health interventions: a review","volume":"122","author":"Turner","year":"2020","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.yebeh.2021.108449_b0080","doi-asserted-by":"crossref","first-page":"e0243424","DOI":"10.1371\/journal.pone.0243424","article-title":"Impact of class-level labelling change on prescriptions of antidepressants for adolescents: an interrupted time-series study using a health insurance claims database in Japan, 2005\u20132013","volume":"15","author":"Ogino","year":"2020","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.yebeh.2021.108449_b0085","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40261-019-00767-8","article-title":"Prescribing trends of codeine-containing medications and other opioids in primary care after a regulatory decision: an interrupted time series analysis","volume":"39","author":"Lombardi","year":"2019","journal-title":"Clin Drug Investig"},{"issue":"9","key":"10.1016\/j.yebeh.2021.108449_b0090","doi-asserted-by":"crossref","first-page":"e029148","DOI":"10.1136\/bmjopen-2019-029148","article-title":"Effect of reimbursement restriction policy on the use of benzodiazepines in the Netherlands: an interrupted time series analysis","volume":"9","author":"Stoker","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.yebeh.2021.108449_b0095","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: From the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"8","key":"10.1016\/j.yebeh.2021.108449_b0100","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.yebeh.2021.108449_b0105","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/pds.3763","article-title":"Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretin","volume":"24","author":"Raguideau","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"10.1016\/j.yebeh.2021.108449_b0110","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/pds.3879","article-title":"for the GENEPI Study Group. Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study","volume":"24","author":"Polard","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.yebeh.2021.108449_b0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.seizure.2019.07.007","article-title":"Trends in sodium valproate prescriptions among children aged 0 to 14 years between 2010 and 2016: A study based on the French National Health Insurance Database","volume":"70","author":"Polard","year":"2019","journal-title":"Seizure"},{"issue":"11","key":"10.1016\/j.yebeh.2021.108449_b0120","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/pds.4881","article-title":"Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016","volume":"28","author":"Charlton","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108449_b0125","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/qshc.2007.023887","article-title":"Long-term effects of a multifaceted intervention to encourage the choice of the oral route for proton pump inhibitors: an interrupted time-series analysis","volume":"18","author":"Colombet","year":"2009","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.yebeh.2021.108449_b0130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/biomet\/38.1-2.159","article-title":"Testing for Serial Correlation in Least Squares Regression","volume":"38","author":"Durbin","year":"1951","journal-title":"II. Biometrika"},{"key":"10.1016\/j.yebeh.2021.108449_b0135","doi-asserted-by":"crossref","unstructured":"Lopez Bernal J, Cummins S, Gasparrini A. The use of controls in interrupted time series studies of public health interventions. Int J Epidemiol 2018.","DOI":"10.1093\/ije\/dyy135"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108449_b0140","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.yebeh.2009.04.026","article-title":"Antiepileptic drug use in women of childbearing age","volume":"15","author":"Meador","year":"2009","journal-title":"Epilepsy Behav EB"},{"key":"10.1016\/j.yebeh.2021.108449_b0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jnnp.70.1.15","article-title":"Additional educational needs in children born to mothers with epilepsy","volume":"70","author":"Adab","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108449_b0150","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/adc.2008.144386","article-title":"Changing trends in antiepileptic drug prescribing in girls of child-bearing potential","volume":"94","author":"Ackers","year":"2009","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.yebeh.2021.108449_b0155","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.seizure.2016.01.019","article-title":"Prescribing trends for sodium valproate in Ireland","volume":"36","author":"Murphy","year":"2016","journal-title":"Seizure"},{"issue":"11","key":"10.1016\/j.yebeh.2021.108449_b0160","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/pds.3847","article-title":"Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regions","volume":"24","author":"Charlton","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.yebeh.2021.108449_b0165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.seizure.2019.07.001","article-title":"Valproate utilisation trends among girls and women from 2013 to 2018","volume":"70","author":"Puteikis","year":"2019","journal-title":"Seizure - Eur J Epilepsy"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108449_b0170","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/practneurol-2018-001931","article-title":"Valproate and epilepsy: for women as well as men","volume":"18","author":"Lawthom","year":"2018","journal-title":"Pract Neurol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021007101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021007101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:42:43Z","timestamp":1761504163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021007101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":34,"alternative-id":["S1525505021007101"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108449","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of recommendations on sodium valproate prescription among women with epilepsy: An interrupted time-series study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108449"}}